Dyne Therapeutics Inc recorded a cumulative net loss of $-519 million during 12 month ending in the second quarter 2026. The Healthcare sector has seen employees of 318 other companies achieving higher income per employee. While Dyne Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3350 to 3987.
Dyne Therapeutics Raises $374.3 Million in Public Offering, Continues to Advance Innovation in Muscle Disease Therapeutics Dyne Therapeutics Inc. announces the successful closing of its underwritten public offering of 12,075,000 shares of common stock at a price of $31.00 per share, generating approximately $374.3 million in gross proceeds. This includes the full exercise by underwriters of their option to purchase an additional 1,575,000 shares. The company, focused on developing life-transforming therapeutics for genetically driven diseases, has managed to secure significant funding to further advance its mission. Despite this promising news, Dyne Therapeutics Inc. recorded a cumulative net loss of $-208 million for the 12-month period ending in the third quarter of 2023. This financial struggle, along with a decline in overall ranking from 2486 to 2499 compared to the second quarter of 2023, highlights the challenges the company is facing in a competitive industry.
Dyne Therapeutics, a clinical-stage muscle disease company specializing in genetic-driven disease therapeutics, has recently concluded its underwritten public offering of common stock, resulting in significant proceeds. The offering, coupled with the company s financial performance in the previous year, has consequential implications for Dyne s growth trajectory and overall standing in the industry.
Dyne Therapeutics,Inc. (Nasdaq:DYN) recently completed its underwritten public offering, issuing approximately 19,722,500 shares of common stock. The offering, priced at $17.50 per share, garnered gross proceeds of approximately $345.1 million for Dyne. Notably, the underwriters exercised their option to purchase an additional 2,572,500 shares of common stock, further bolstering the company s financial standing.
Dyne Therapeutics Plans Underwritten Public Offering of $175 Million in Common Stock Dyne Therapeutics, a clinical-stage muscle disease company specializing in therapeutics for genetically driven diseases, has recently announced the commencement of an underwritten public offering. The company aims to raise $175 million by selling shares of its common stock. In addition, Dyne intends to grant the underwriters a 30-day option to purchase up to an additional $26.25 million of shares. It is important to note that all the shares in the proposed offering will be sold by Dyne. Despite Dyne Therapeutics recent financial performance, with a cumulative net loss of $208 million for the 12 months ending in the third quarter of 2023, the company believes that this public offering will pave the way for future growth and development. However, it is worth mentioning that the Major Pharmaceutical Preparations industry has witnessed employees in 65 other companies achieving higher income per employee than Dyne.
Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
